Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Section of Urology, Durham VA Medical Center, Durham, NC, USA.
Future Oncol. 2023 Oct;19(31):2075-2082. doi: 10.2217/fon-2023-0354. Epub 2023 Aug 30.
WHAT IS THIS SUMMARY ABOUT?: This is a plain language summary of a research article originally published in . The original article described the effect of rapidly rising prostate-specific antigen (PSA) levels on how long men with a type of advanced prostate cancer live and their healthcare costs. The prostate is a part of the male body that helps make semen. PSA is a protein produced by the prostate that can show how advanced prostate cancer has become. One measure of prostate cancer growth is assessing how quickly a patient's PSA level doubles. This is known as the PSA doubling time (PSADT). People with a shorter PSADT usually have faster-growing prostate cancer compared with people who have a longer PSADT of more than 12 months (long PSADT). Researchers wanted to know if PSADT can predict cancer spread (known as metastasis) or death for people with a type of advanced prostate cancer called non-metastatic castration-resistant prostate cancer (nmCRPC). Researchers also wanted to know if PSADT can predict healthcare costs. This could help doctors choose the right treatment for their patients with nmCRPC. This was a real-world study, not a clinical trial. This means that researchers looked at what happened when men received the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers used insurance claim information.
WHAT WERE THE RESULTS?: Researchers looked at information for 2800 men with nmCRPC. Six out of every 10 men (60%) had a long PSADT of more than 12 months. Researchers found that it took longer for the cancer to spread to other parts of the body in men with a longer PSADT than men with PSADT of 12 months or less. Researchers also found that men with a longer PSADT lived longer than men with PSADT of 12 months or less. The long PSADT group had fewer healthcare visits overall than men with PSADT of 10 months or less. Over time, it cost less to treat men with a long PSADT than men with PSADT of 10 months or less. Generally, if PSADT was shorter, patients tended to do worse.
WHAT DO THE RESULTS OF THE STUDY MEAN?: In this real-world study, researchers found that men with nmCRPC lived longer and had lower healthcare costs if they had a long PSADT of more than 12 months compared with men who had a shorter PSADT. Men with nmCRPC and a shorter PSADT may benefit from approved treatments that slow cancer spread and help them live longer. However, these treatments may have side effects and cost more than standard treatment. Doctors take all these things into account when choosing treatments for their patients. Most men in this study had a long PSADT of more than 12 months. Standard treatment may be the right choice for them because they are more likely to have better outcomes than men with a shorter PSADT.
这是一篇原始研究文章的通俗易懂的总结。原始文章描述了前列腺特异性抗原 (PSA) 水平迅速升高对患有某种类型晚期前列腺癌的男性寿命以及医疗保健成本的影响。前列腺是男性体内帮助产生精液的一部分。PSA 是一种由前列腺产生的蛋白质，可以显示出前列腺癌已经发展到何种程度。评估患者 PSA 水平翻倍所需的时间是前列腺癌生长的一种衡量标准。这被称为 PSA 倍增时间 (PSADT)。与 PSADT 超过 12 个月（长 PSADT）的患者相比，PSADT 较短的患者通常具有更快的前列腺癌生长速度。研究人员想知道 PSADT 是否可以预测患有一种称为非转移性去势抵抗性前列腺癌 (nmCRPC) 的晚期前列腺癌患者的癌症扩散（称为转移）或死亡。研究人员还想知道 PSADT 是否可以预测医疗保健成本。这可以帮助医生为患有 nmCRPC 的患者选择正确的治疗方法。这是一项真实世界的研究，而不是临床试验。这意味着研究人员观察了男性在接受医生规定的治疗时的情况，这些治疗是他们常规医疗保健治疗的一部分。在这项研究中，研究人员使用了保险索赔信息。
研究人员观察了 2800 名患有 nmCRPC 的男性的信息。每 10 名男性中就有 6 名（60%）的 PSADT 超过 12 个月。研究人员发现，与 PSADT 为 12 个月或更短的男性相比，PSADT 较长的男性癌症向身体其他部位扩散需要更长的时间。研究人员还发现，PSADT 较长的男性比 PSADT 为 12 个月或更短的男性寿命更长。PSADT 较长的男性总体上的就诊次数少于 PSADT 为 10 个月或更短的男性。随着时间的推移，治疗 PSADT 较长的男性的成本低于治疗 PSADT 为 10 个月或更短的男性。一般来说，如果 PSADT 较短，则患者的病情往往更糟。
在这项真实世界的研究中，研究人员发现，与 PSADT 较短的男性相比，患有 nmCRPC 的男性如果 PSADT 超过 12 个月，他们的寿命更长，医疗保健成本更低。患有 nmCRPC 和 PSADT 较短的男性可能受益于减缓癌症扩散并帮助他们延长寿命的批准治疗方法。然而，这些治疗方法可能有副作用，并且比标准治疗费用更高。医生在为患者选择治疗方法时会考虑所有这些因素。这项研究中的大多数男性 PSADT 都超过 12 个月。标准治疗可能是他们的正确选择，因为与 PSADT 较短的男性相比，他们更有可能获得更好的结果。
